Competition Commission of India (CCI) keeps a tab on unfair trade practices across sectors.
Combinations or mergers and acquisitions (M&As) between entities beyond a certain threshold are required to get CCI nod.
Sikri, who took over as Chairman in January, has said remedies are suggested depending on the nature of combination and its impact in the relevant market.
In less than two years, the watchdog has put three major deals for public scrutiny following anti-competitive concerns.
More From This Section
The newsletter is for the period from October-December 2015.
According to Sikri, the commission may choose a behavioural or structural remedy or even a hybrid remedy, depending on the nature of the combination and its impact on competition in the relevant market.
Noting that the regulator has completed more than four years of effective and timely review of combination cases, he also said the experience has been that most "combinations do not raise competition concerns".
Back in 2014, the watchdog had sought comments from public on two mega transactions -- the USD 4 billion Sun Pharma-Ranbaxy combination and Holcim-Lafarge deal.
In both instances, the regulator had called for divestment of certain assets by the entities involved to address anti-competition concerns.